drugset
drugset / Trial / NCT07800429

Effect of a Known P-glycoprotein (P-gp) Inhibitor, Itraconazole, on the Pharmacokinetics (PK) of Engasertib

NCT07800429 ↗

Phase 1 Not yet recruiting 27 enrolled Vaderis Therapeutics AG
NaSequentialOpen-labelBasic science

Summary

The primary objective of this trial is to assess the effect of a known P-gp inhibitor, itraconazole, on the PK of engasertib in healthy adult participants.

Timeline

Start
2026-09
Primary completion
2026-10
Completion
2026-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Itraconazole Small molecule 200 mg Oral
Subject VAD044 Small molecule 40 mg Oral

Indications

No indication recorded.